Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials

INTRODUCTION: In a retrospective analysis of two randomized phase III trials in mCRC patients treated first line with oxaliplatin, fluoropyrimidine with and without Bevacizumab (the AIO KRK 0207 and R091 trials) we evaluated the association of high microsatellite instability (MSI-H), immunoscore (IS...

Descripción completa

Detalles Bibliográficos
Autores principales: Noepel-Duennebacke, Stefanie, Juette, Hendrik, Schulmann, Karsten, Graeven, Ulrich, Porschen, Rainer, Stoehlmacher, Jan, Hegewisch-Becker, Susanna, Raulf, Arne, Arnold, Dirk, Reinacher-Schick, Anke, Tannapfel, Aandrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397637/
https://www.ncbi.nlm.nih.gov/pubmed/33675399
http://dx.doi.org/10.1007/s00432-021-03559-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397637/
https://www.ncbi.nlm.nih.gov/pubmed/33675399
http://dx.doi.org/10.1007/s00432-021-03559-w

Ejemplares similares